NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00045032,Herceptin (Trastuzumab) in Treating Women With Human Epidermal Growth Factor Receptor (HER) 2-Positive Primary Breast Cancer,https://clinicaltrials.gov/study/NCT00045032,HERA,COMPLETED,"The purpose of this trial is to evaluate Herceptin treatment for 1 year and 2 years (versus observation/no Herceptin) in women with HER2-overexpressing primary breast cancer who have completed (neo-)adjuvant systemic chemotherapy, definitive surgery, and radiotherapy, if applicable. Efficacy and safety will be assessed for 10 years from randomization for each participant. All participants will continue to be followed for survival until 10 years after enrollment of the last participant.",YES,Breast Cancer,DRUG: Herceptin|DRUG: Herceptin,"Percentage of Participants With Disease-Free Survival (DFS) Events in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-Up, DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants with at least one DFS event was reported. The analysis of the Herceptin 1-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed by the Sponsor in 2006 following database cleaning. The analysis of the Herceptin 2-Year Arm against the Observation Arm was performed for an Independent Data Monitoring Committee (IDMC) in 2005 at a time the Sponsor was blinded. Therefore, these data are reported under a separate Outcome Measure., From Baseline until time of event (median of 1 year)|Percentage of Participants With DFS Events in Herceptin 2-Year Arm Compared to Observation: 1-Year Median Follow-Up, DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants with at least one DFS event was reported. The analysis of the Herceptin 2-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed for an IDMC in 2005 at a time the Sponsor was blinded. The analysis of the Herceptin 1-Year Arm against the Observation Arm was performed by the Sponsor in 2006 following database cleaning. Therefore, these data are reported under a separate Outcome Measure., From Baseline until time of event (median of 1 year)|DFS Rate According to Kaplan-Meier Analysis in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-Up, DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95 percent (%) confidence interval (CI) were estimated by Kaplan-Meier analysis based on available data at the time of the 1-year median follow-up analysis. The analysis of the Herceptin 1-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed by the Sponsor in 2006 following database cleaning. The analysis of the Herceptin 2-Year Arm against the Observation Arm was performed for an IDMC in 2005 at a time the Sponsor was blinded. Therefore, these data are reported under a separate Outcome Measure., Year 2|DFS Rate According to Kaplan-Meier Analysis in Herceptin 2-Year Arm Compared to Observation: 1-Year Median Follow-Up, DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 1-year median follow-up analysis. The analysis of the Herceptin 2-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed for an IDMC in 2005 at a time the Sponsor was blinded. The analysis of the Herceptin 1-Year Arm against the Observation Arm was performed by the Sponsor in 2006 following database cleaning. Therefore, these data are reported under a separate Outcome Measure., Year 2|Percentage of Participants With DFS Events Compared to Observation: 8-Year Median Follow-Up, DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants with at least one DFS event was reported., From Baseline until time of event (median of 8 years)|DFS Rate at Year 3 According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up, DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis., Year 3|DFS Rate at Year 5 According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up, DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis., Year 5|DFS Rate at Year 7 According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up, DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis., Year 7|DFS Rate at Year 8 According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up, DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis., Year 8|Percentage of Participants With DFS Events Compared to Observation: 10-Year Maximum Follow-Up, DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants with at least one DFS event was reported., From Baseline until time of event (maximum of 10 years)|DFS Rate at Year 3 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up, DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events., Year 3|DFS Rate at Year 5 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up, DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events., Year 5|DFS Rate at Year 7 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up, DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events., Year 7|DFS Rate at Year 8 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up, DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events., Year 8|DFS Rate at Year 9 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up, DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events., Year 9|DFS Rate at Year 10 According to Kaplan-Meier Analysis Compared to Observation: 10-Year Maximum Follow-Up, DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events., Year 10","Percentage of Participants With DFS Events in 1-Year Versus 2-Year Herceptin: 10-Year Maximum Follow-Up, DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants with at least one DFS event was reported., From Baseline until time of event (maximum of 10 years)|DFS Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 10-Year Maximum Follow-Up, DFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer or second non-breast malignancy other than basal or squamous carcinoma of the skin and carcinoma in situ of the cervix, or death from any cause. The percentage of participants free of DFS events (i.e., the DFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with a 10-year maximum follow-up for DFS events., Years 3, 5, 7, 8, 9, 10|Percentage of Participants With Overall Survival (OS) Events in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-Up, OS events referred to death from any cause. The percentage of participants who died was reported. The analysis of the Herceptin 1-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed by the Sponsor in 2006 following database cleaning. The analysis of the Herceptin 2-Year Arm against the Observation Arm was performed for an IDMC in 2005 at a time the Sponsor was blinded. Therefore, these data are reported under a separate Outcome Measure., From Baseline until time of event (median of 1 year)|Percentage of Participants With OS Events in Herceptin 2-Year Arm Compared to Observation: 1-Year Median Follow-Up, OS events referred to death from any cause. The percentage of participants who died was reported. The analysis of the Herceptin 2-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed for an IDMC in 2005 at a time the Sponsor was blinded. The analysis of the Herceptin 1-Year Arm against the Observation Arm was performed by the Sponsor in 2006 following database cleaning. Therefore, these data are reported under a separate Outcome Measure., From Baseline until time of event (median of 1 year)|OS Rate According to Kaplan-Meier Analysis in Herceptin 1-Year Arm Compared to Observation: 1-Year Median Follow-Up, OS events referred to death from any cause. The percentage of participants alive (i.e., the OS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 1-year median follow-up analysis. The analysis of the Herceptin 1-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed by the Sponsor in 2006 following database cleaning. The analysis of the Herceptin 2-Year Arm against the Observation Arm was performed for an IDMC in 2005 at a time the Sponsor was blinded. Therefore, these data are reported under a separate Outcome Measure., Year 2|OS Rate According to Kaplan-Meier Analysis in Herceptin 2-Year Arm Compared to Observation: 1-Year Median Follow-Up, OS events referred to death from any cause. The percentage of participants alive (i.e., the OS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 1-year median follow-up analysis. The analysis of the Herceptin 2-Year Arm against the Observation Arm after 1-year median follow-up, as reported below, was performed for an IDMC in 2005 at a time the Sponsor was blinded. The analysis of the Herceptin 1-Year Arm against the Observation Arm was performed by the Sponsor in 2006 following database cleaning. Therefore, these data are reported under a separate Outcome Measure., Year 2|Percentage of Participants With OS Events Compared to Observation: 8-Year Median Follow-Up, OS events referred to death from any cause. The percentage of participants who died was reported., From Baseline until time of event (median of 8 years)|OS Rate According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up, OS events referred to death from any cause. The percentage of participants alive (i.e., the OS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis., Years 3, 5, 7, 8|Percentage of Participants With OS Events Compared to Observation: 11-Year Median Follow-Up, OS events referred to death from any cause. The percentage of participants who died was reported., From Baseline until time of event (median of 11 years)|OS Rate According to Kaplan-Meier Analysis Compared to Observation: 11-Year Median Follow-Up, OS events referred to death from any cause. The percentage of participants alive (i.e., the OS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with an 11-year median follow-up for OS events., Years 3, 5, 7, 9, 10, 11, 12|Percentage of Participants With OS Events in 1-Year Versus 2-Year Herceptin: 11-Year Median Follow-Up, OS events referred to death from any cause. The percentage of participants who died was reported., From Baseline until time of event (median of 11 years)|OS Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 11-Year Median Follow-Up, OS events referred to death from any cause. The percentage of participants alive (i.e., the OS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the final analysis with an 11-year median follow-up for OS events., Years 3, 5, 7, 9, 10, 11, 12|Percentage of Participants With Recurrence-Free Survival (RFS) Events Compared to Observation: 8-Year Median Follow-Up, RFS events included local, regional, or distant tumor recurrence. The percentage of participants with at least one RFS event was reported., From Baseline until time of event (median of 8 years)|RFS Rate According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up, RFS events included local, regional, or distant tumor recurrence. The percentage of participants free of RFS events (i.e., the RFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis., Years 3, 5, 7, 8|Percentage of Participants With RFS Events in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up, RFS events included local, regional, or distant tumor recurrence. The percentage of participants with at least one RFS event was reported., From Baseline until time of event (median of 8 years)|RFS Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up, RFS events included local, regional, or distant tumor recurrence. The percentage of participants free of RFS events (i.e., the RFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis., Years 3, 5, 7, 8|Percentage of Participants With Distant Disease-Free Survival (DDFS) Events Compared to Observation: 8-Year Median Follow-Up, DDFS events included distant tumor recurrence, second primary cancer, or contralateral breast cancer. The percentage of participants with at least one DDFS event was reported., From Baseline until time of event (median of 8 years)|DDFS Rate According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up, DDFS events included distant tumor recurrence, second primary cancer, or contralateral breast cancer. The percentage of participants free of DDFS events (i.e., the DDFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis., Years 3, 5, 7, 8|Percentage of Participants With DDFS Events in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up, DDFS events included distant tumor recurrence, second primary cancer, or contralateral breast cancer. The percentage of participants with at least one DDFS event was reported., From Baseline until time of event (median of 8 years)|DDFS Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up, DDFS events included distant tumor recurrence, second primary cancer, or contralateral breast cancer. The percentage of participants free of DDFS events (i.e., the DDFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis., Years 3, 5, 7, 8|Percentage of Participants With Tumor Recurrence (TR) Compared to Observation: 8-Year Median Follow-Up, The percentage of participants with TR of the present breast cancer was reported. TR included local, regional, or distant tumor ignoring contralateral breast cancer and second non-breast malignancy., From Baseline until time of event (median of 8 years)|TR-Free Rate According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up, The percentage of participants without TR of the present breast cancer (i.e., the TR-free rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis. TR included local, regional, or distant tumor ignoring contralateral breast cancer and second non-breast malignancy., Years 3, 5, 7, 8|Percentage of Participants With TR in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up, The percentage of participants with TR of the present breast cancer was reported. TR included local, regional, or distant tumor ignoring contralateral breast cancer and second non-breast malignancy., From Baseline until time of event (median of 8 years)|TR-Free Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up, The percentage of participants without TR of the present breast cancer (i.e., the TR-free rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis. TR included local, regional, or distant tumor ignoring contralateral breast cancer and second non-breast malignancy., Years 3, 5, 7, 8|Percentage of Participants With Distant Tumor Recurrence (DTR) Compared to Observation: 8-Year Median Follow-Up, The percentage of participants with DTR was reported. DTR included distant tumors ignoring local and regional recurrences, contralateral breast cancer, and second non-breast malignancy., From Baseline until time of event (median of 8 years)|DTR-Free Rate According to Kaplan-Meier Analysis Compared to Observation: 8-Year Median Follow-Up, The percentage of participants without DTR (i.e., the DTR-free rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis. DTR included distant tumors ignoring local and regional recurrences, contralateral breast cancer, and second non-breast malignancy., Years 3, 5, 7, 8|Percentage of Participants With DTR in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up, The percentage of participants with DTR was reported. DTR included distant tumors ignoring local and regional recurrences, contralateral breast cancer, and second non-breast malignancy., From Baseline until time of event (median of 8 years)|DTR-Free Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up, The percentage of participants without DTR (i.e., the DTR-free rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis. DTR included distant tumors ignoring local and regional recurrences, contralateral breast cancer, and second non-breast malignancy., Years 3, 5, 7, 8|Percentage of Participants With Restricted Disease-Free Survival (RDFS) Events in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up, RDFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer, or death from any cause. The percentage of participants with at least one RDFS event was reported., From Baseline until time of event (median of 8 years)|RDFS Rate According to Kaplan-Meier Analysis in 1-Year Versus 2-Year Herceptin: 8-Year Median Follow-Up, RDFS events included loco-regional or distant recurrence of breast cancer, development of contralateral breast cancer, or death from any cause. The percentage of participants free of RDFS events (i.e., the RDFS rate) and corresponding 95% CI were estimated by Kaplan-Meier analysis based on available data at the time of the 8-year median follow-up analysis., Years 3, 5, 7, 8|Percentage of Participants With Primary Cardiac Endpoint Events Compared to Observation: 10-Year Maximum Follow-Up, Primary cardiac endpoint events included the occurrence of any of the following between randomization and new therapy for recurrent disease: symptomatic New York Heart Association (NYHA) Class III or IV congestive heart failure (CHF) confirmed by a cardiologist with a drop in left ventricular ejection fraction (LVEF) at least 10 percentage points from Baseline and to a value less than (\<) 50%, and documentation of definite or probable cardiac death. Definite cardiac death included CHF, myocardial infarction, or primary arrhythmia. Probable cardiac death included unexpected sudden death within 24 hours of a cardiac event (syncope, cardiac arrest, chest pain, infarction, arrhythmia) without documented etiology. The percentage of participants with at least one primary cardiac endpoint event was reported. The 95% CI was calculated by the Pearson-Clopper method for a one-sample binomial., From Baseline until time of event (maximum up to 10 years)|Percentage of Participants With Secondary Cardiac Endpoint Events Compared to Observation: 10-Year Maximum Follow-Up, Secondary cardiac endpoint events included NYHA Class I or II CHF with a drop in LVEF measured by multiple-gated acquisition or electrocardiogram, unless the subsequent assessment of LVEF indicated a return to levels that did not meet the definition of a significant LVEF drop. A significant LVEF drop was defined as an absolute reduction of at least 10 percentage points from Baseline and to a value \<50%. The percentage of participants with at least one secondary cardiac endpoint event was reported, excluding those with both a primary and secondary cardiac endpoint event. The 95% CI was calculated by the Pearson-Clopper method for a one-sample binomial., From Baseline until time of event (maximum up to 10 years)",,Hoffmann-La Roche,Breast International Group|European Organisation for Research and Treatment of Cancer - EORTC|NCIC Clinical Trials Group|ETOP IBCSG Partners Foundation,FEMALE,"ADULT, OLDER_ADULT",PHASE3,5099,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,BO16348|BIG-01-01|EU-20216|ROCHE-B016348E|ROCHE-B016348C|EORTC-10011|CAN-NCIC-MA24|IBCSG-28-02,2001-11,2005-03,2015-06,2003-01-27,2017-04-27,2017-04-27,"Hospital Aleman de Buenos Aires, Buenos Aires, 1118, Argentina|Saint John of God Hospital, Geelong, Australian Capital Territory, 3220, Australia|Toowoomba Hospital, Toowoomba, Queensland, 4350, Australia|Andrew Love Cancer Centre, Geelong, Victoria, 3220, Australia|Mount Hospital, Perth, Western Australia, 6000, Australia|Landeskrankenhaus Feldkirch, Feldkirch-Tisis, 6807, Austria|Innsbruck Universitaetsklinik, Innsbruck, A-6020, Austria|Landeskrankenhaus Klagenfurt, Klagenfurt, 9026, Austria|St. Vincent's Hospital, Linz Donau, A-4010, Austria|Landeskrankenanstalten - Salzburg, Salzburg, A-5020, Austria|Landeskrankenhaus St. Poelten, St. Poelten, 3100, Austria|Universitaetsklinik fuer Innere Medizin I, Vienna, 1090, Austria|Wilhelminenspital der Stadt Wien, Vienna, A-1160, Austria|LKH Villach, Villach, 9500, Austria|LKH Voecklabruck, Voecklabruck, 4840, Austria|A. oe. Krankenhaus Wiener Neustadt, Wiener Neustadt, A-2700, Austria|Ziekenhuis Netwerk Antwerpen Middelheim, Antwerp, 2020, Belgium|Reseau Hospitalier De Medecine Sociale, Baudour, 7331, Belgium|Hopital Universitaire Erasme, Brussels, 1070, Belgium|Academisch Ziekenhuis der Vrije Universiteit Brussel, Brussels, 1090, Belgium|Institut Jules Bordet, Brussels, B-1000, Belgium|Centre Hospitalier Notre Dame - Reine Fabiola, Charleroi, 6000, Belgium|Cazk Groeninghe - Campus St-Niklaas, Kortrijk, B-8500, Belgium|Centre Hospitalier Universitaire de Tivoli, La Louviere, 7100, Belgium|U.Z. Gasthuisberg, Leuven, B-3000, Belgium|Clinique Saint-Joseph, Liege, B 4000, Belgium|CHU Liege - Domaine Universitaire du Sart Tilman, Liege, B-4000, Belgium|Clinique Sainte Elisabeth, Namur, 5000, Belgium|Hospital Serruys Ziekenhuis, Oostende, 8400, Belgium|Centre Hospitalier Peltzer-La Tourelle, Verviers, B-4800, Belgium|Porto Alegre Hospital, Porto Alegre, Rio Grande do Sul, 90035-003, Brazil|Hospital Sao Lucas da PUCRS, Porto Alegre, 90610-000, Brazil|Hospital Santa Rita, Porto Alegre, 91330-490, Brazil|Instituto Nacional de Cancer, Rio de Janeiro, 20560-120, Brazil|Faculdade De Medicina Do ABC, Santo Andre, 09060-650, Brazil|Tom Baker Cancer Centre - Calgary, Calgary, Alberta, T2N 4N2, Canada|British Columbia Cancer Agency - Centre for the Southern Interior, Kelowna, British Columbia, V1Y 5L3, Canada|Fraser Valley Cancer Centre at British Columbia Cancer Agency, Surrey, British Columbia, V3V 1Z2, Canada|British Columbia Cancer Agency - Vancouver Cancer Centre, Vancouver, British Columbia, V5Z 4E6, Canada|British Columbia Cancer Agency - Vancouver Island Cancer Centre, Victoria, British Columbia, V8R 6V5, Canada|CancerCare Manitoba, Winnipeg, Manitoba, R2H 2A6, Canada|Royal Victoria Hospital of Barrie, Barrie, Ontario, L4M 6M2, Canada|Margaret and Charles Juravinski Cancer Centre, Hamilton, Ontario, L8V 5C2, Canada|Trillium Health Centre - Mississauga Site, Mississauga, Ontario, L5B 1B8, Canada|Algoma Regional Cancer Program at Sault Area Hospital, Sault Sainte Marie, Ontario, P6A 2C4, Canada|Hotel Dieu Health Sciences Hospital - Niagara, St. Catharines, Ontario, L2R 5K3, Canada|Toronto East General Hospital, Toronto, Ontario, M4C 3E7, Canada|Mount Sinai Hospital - Toronto, Toronto, Ontario, M5G 1X5, Canada|Princess Margaret Hospital, Toronto, Ontario, M5G 2M9, Canada|Windsor Regional Cancer Centre at Windsor Regional Hospital, Windsor, Ontario, N8W 2X3, Canada|Prince Edward Island Cancer Centre at Queen Elizabeth Hospital, Charlottetown, Prince Edward Island, C1A 8T5, Canada|Hopital du Saint-Sacrement, Quebec, Quebec City, Quebec, G1S 4L8, Canada|Allan Blair Cancer Centre at Pasqua Hospital, Regina, Saskatchewan, S4T 7T1, Canada|Saskatoon Cancer Centre at the University of Saskatchewan, Saskatoon, Saskatchewan, S7N 4H4, Canada|Fundacion Arturo Lopez Perez, Santiago, 29, Chile|Hospital Clinico San Borja Arriaran, Santiago, Chile|Hospital Dr. Sotero Del Rio, Santiago, Chile|Hospital Militar, Santiago, Chile|Instituto Nacional Del Cancer, Santiago, Chile|Queen Mary Hospital, Hong Kong, China|Tuen Mun Hospital, Hong Kong, China|Tongji Medical University, Wuhan, 430030, China|Instituto Nacional De Cancerologia, Bogota, Colombia|Clinical Hospital Center Split, Split, 21000, Croatia|Centralsygehus I Esbjerg, Esbjerg, 6700, Denmark|Herning Central Hospital, Herning, 7400, Denmark|Hillerod Hospital, Hillerod, 3400, Denmark|Centralsygehuset I Naestved, Naestved, 4700, Denmark|Sonderborg Sygehus, Sonderborg, 6400, Denmark|Centre Regional Francois Baclesse, Caen, 14076, France|Centre Hospital Regional Universitaire de Limoges, Limoges, 87042, France|Hopital Clinique Claude Bernard, Metz, 57072, France|Charite - Campus Charite Mitte, Berlin, D-10117, Germany|Evangelisches Bethesda Krankenhaus GmbH, Essen, D-45355, Germany|Universitaetsklinikum Freiburg, Freiburg, D-79106, Germany|Martin Luther Universitaet, Halle, D-06097, Germany|Henriettenstiftung Krankenhaus, Hanover, D-30559, Germany|Universitaets-Hautklinik Heidelberg, Heidelberg, D-69115, Germany|St. Vincentius-Kliniken, Karlsruhe, D-76137, Germany|University Hospital Schleswig-Holstein - Kiel Campus, Kiel, D-24105, Germany|Kreiskrankenhaus Leonberg - Frauenklinik, Leonberg, D-71229, Germany|Universitaetsklinkum Magdeburg der Otto-von-Guericke-Universitaet Magdeburg, Magdeburg, D-39120, Germany|Frauenklinik Vom Roten Kreuz, Munich, 80637, Germany|Klinikum Rechts Der Isar - Technische Universitaet Muenchen, Munich, D-81675, Germany|Frauenklinik - Universitaetsklinikum Rostock am Klinikum Sudstadt, Rostock, D-18059, Germany|Universitaet Ulm, Ulm, D-89075, Germany|Dr. Horst-Schmidt-Kliniken, Wiesbaden, D-65199, Germany|University of Crete School of Medicine, Heraklion, Crete, 71110, Greece|Evaggelismos Hospital, Athens, 10676, Greece|Centro Medico, Guatemala City, 01010, Guatemala|Hospital Roosevelt, Guatemala City, 01010, Guatemala|Prince of Wales Hospital, Shatin, New Territories, Hong Kong|Semmelweis University, Budapest, 1082, Hungary|National Institute of Oncology, Budapest, 1122, Hungary|Fovarosi Onkormanyzat Szent Margit Korhaz, Okologia, Budapest, H-1032, Hungary|Cork University Hospital, Cork, Ireland|Sieff Hospital, Safed, 13110, Israel|Ospedale San Lazzaro, Alba, 12051, Italy|Ospedale Presenti Fenaroli, Alzano-Lombardo, 24022, Italy|Centro di Riferimento Oncologico - Aviano, Aviano, 33081, Italy|Ospedali Riuniti di Bergamo, Bergamo, 24100, Italy|Ospedale degli Infermi - ASL 12, Biella, 13900, Italy|Ospedale Bellaria, Bologna, I-40139, Italy|Spedali Civili di Brescia, Brescia, 25124, Italy|Ospedale Oncologico A. Businco, Cagliari, 09100, Italy|Ospedale B. Ramazzini, Carpi, 41012, Italy|Ospedale Valduce, Como, 22100, Italy|Ospedale Santa Croce, Cuneo, 12100, Italy|Universita Degli Studi Di Florence, Firenze (Florence), 50121, Italy|Azienda Ospedaliero Careggi, Florence, 50139, Italy|Morgagni-Pierantoni Ospedale, Forli, 47100, Italy|Istituto Nazionale per la Ricerca sul Cancro, Genoa, 16132, Italy|Ospedale A. Manzoni, Lecco, 23900, Italy|Presidio Ospedaliero, Livorno, 57100, Italy|Carlo Poma Hospital, Mantova, 46100, Italy|European Institute of Oncology, Milan, 20141, Italy|Ospedale Niguarda Ca'Granda, Milan, 20162, Italy|University of Modena Hospital and Reggio Emilia School of Medicine, Modena, 41100, Italy|Azienda Ospedaliera Di Parma, Parma, 43100, Italy|I.R.C.C.S. Policlinico San Matteo, Pavia, 27100, Italy|Policlinico Monteluce, Perugia, 06122, Italy|Azienda Ospedaliera, Reggio Emilia, 42100, Italy|Ospedale San Filippo Neri, Rome, 00135, Italy|Ospedale Sant' Eugenio, Rome, 00144, Italy|Istituto Clinico Humanitas, Rozzano, 20089, Italy|Ospedale Civile ASL 1, Sassari, 07100, Italy|Primario U.O. di Oncologia Medica, Trento, 38100, Italy|Ospedale Ostetrico Ginecologica Sant Anna, Turin, 10126, Italy|Universita di Torino, Turin, 10126, Italy|Tokai University School Of Medicine, Kanagawa, 259-1193, Japan|Tokyo Metropolitan - Komagome Hospital, Tokyo, 113-8677, Japan|Seoul National University Hospital, Seoul, 110-744, Korea, Republic of|Yonsei Cancer Center at Yonsei University Medical Center, Seoul, 120-752, Korea, Republic of|Academisch Ziekenhuis Maastricht, Maastricht, 6202 AZ, Netherlands|Maasland Hospital, Sittard, 6131 BK, Netherlands|Diakonessenhuis Utrecht, Utrecht, 3508 TG, Netherlands|Medical University of Gdansk, Gdansk, 80-211, Poland|Oncologic Center, Gliwice, 44-101, Poland|Medical University, Poznan, 61-878, Poland|Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, 02-781, Poland|Instituto Portugues de Oncologia, Centro Regional de Coimbra, Coimbra, 3000-075, Portugal|Hospitais da Universidade de Coimbra (HUC), Coimbra, 3000, Portugal|Maternidade Byssaia Barreto, Coimbra, 3000, Portugal|Hospital Distrital De Faro, Faro, 8000, Portugal|University Hospital of Santa Maria, Lisboa, 1649-035, Portugal|Instituto Portugues de Oncologia de Francisco Gentil - Centro Regional de Oncologia de Lisboa, S.A., Lisbon, 1099-023 Codex, Portugal|Moscow Oncology Hospital, Moscow, 107005, Russian Federation|P.A. Hertzen Research Oncology Institute, Moscow, 125284, Russian Federation|Johns Hopkins Singapore International Medical Centre, Singapore, 308433, Singapore|Groote Schuur Hospital, Cape Town, 7925, South Africa|Parklands Hospital, Durban, 4001, South Africa|Sandton Oncology Centre, Johannesburg, 2121, South Africa|Medical Oncology Centre of Rosebank, Johannesburg, 2193, South Africa|Pretoria - East Hospital, Lynnwood, 0081, South Africa|Hospital De La Ribera, Alzira, 46600, Spain|Hospital Del Mar, Barcelona, 08003, Spain|Hospital Universitario San Cecilio de Granada, Granada, 18003, Spain|Hospital General Universitario De Guadalajara, Guadalajara, 19002, Spain|Hospital Juan Ramon Jimenez, Huelva, 21005, Spain|Hospital Cuidad de Jaen, Jaen, 23007, Spain|Centro Oncologico De Galicia Jose Antonio Quirogay Pineyro, La Coruna, 15009, Spain|Hospital Universitario Canarias, La Laguna, 38320, Spain|Hospital de Gran Canaria Dr. Negrin, Las Palmas de Gran Canaria, 35020, Spain|Hospital Insular de Gran Canaria, Las Palmas, G.C., Spain|Hospital de la Princesa, Madrid, 28006, Spain|Complejo Hospitalario Santa Maria, Orense, 32005, Spain|Complejo Hospitalario de Pontevedra, Pontevedra, 36001, Spain|Consorci Hospitalari del Parc Tauli, Sabadell, 08208, Spain|Hospital Universitario Nuestra Senora de la Candelaria, Santa Cruz de Tenerife, 38010, Spain|Hospital Universidad Virgen Del Rocio, Sevilla, E- 41013, Spain|Hospital Virgen Del La Salud, Toledo, 45004, Spain|Hospital General Universitario Valencia, Valencia, 41014, Spain|Complexo Hospitalario Xeral de Vigo, Vigo Pontevedra, 36204, Spain|Hospital Universitario Miguel Servet, Zaragoza, 59009, Spain|University Hospital of Linkoping, Linkoping, S-581 85, Sweden|University Hospital of Malmoe, Malmo, 20502, Sweden|Sahlgrenska University Hospital - Molndal at Gothenburg University, Molndal, S-43180, Sweden|Karolinska University Hospital - Huddinge, Stockholm, S-171 76, Sweden|Umea Universitet, Umea, SE-901 87, Sweden|Uppsala University Hospital, Uppsala, SE-75185, Sweden|Kantonspital Aarau, Aarau, 5001, Switzerland|Universitaetsspital-Basel, Basel, CH-4031, Switzerland|Inselspital Bern, Bern, CH-3010, Switzerland|Spitaeler Chur AG, Chur, CH-7000, Switzerland|Centre Hospitalier Universitaire Vaudois, Lausanne, CH-1011, Switzerland|Ospedale Beata Vergine, Mendrisio, CH-6850, Switzerland|Kantonsspital - St. Gallen, St. Gallen, CH-9007, Switzerland|UniversitaetsSpital Zuerich, Zurich, CH-8091, Switzerland|Chulalongkorn University Hospital, Bangkok, 10330, Thailand|Ramathibodi Hospital, Bangkok, 10400, Thailand|Bradford Hospitals NHS Trust, Bradford, England, BD9 6RJ, United Kingdom|Broomfield Hospital, Chelmsford, Essex, England, CM1 7ET, United Kingdom|Saint Margaret's Hospital, Epping Essex, England, CM16 6TN, United Kingdom|Diana Princess of Wales Hospital, Grimsby, England, DN33 2BA, United Kingdom|Huddersfield Royal Infirmary, Huddersfield, West Yorks, England, HD3 3EA, United Kingdom|Princess Royal Hospital, Hull, England, HU8 9HE, United Kingdom|Cookridge Hospital at Leeds Teaching Hospital NHS Trust, Leeds, England, LS16 6QB, United Kingdom|Imperial College of Medicine, London, England, W12 0NN, United Kingdom|James Cook University Hospital, Middlesbrough, England, TS4 3BW, United Kingdom|Northern Centre for Cancer Treatment at Newcastle General Hospital, Newcastle-Upon-Tyne, England, NE4 6BE, United Kingdom|Cancer Research Centre at Weston Park Hospital, Sheffield, England, S1O 2SJ, United Kingdom|Airedale General Hospital, West Yorkshire, England, BD20 6TD, United Kingdom|Southend NHS Trust Hospital, Westcliff-On-Sea, England, SS0 0RY, United Kingdom",
